Some take short walks, others divide large tasks into small pieces
Gut microbiota composition has emerged as a potential modulator of GLP-1 production, though human evidence remains limited
Astrup A, Rssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al
Obesity: seize the day, fight the fat
This was despite the fact that the work behind the patent, filed in 1997 and granted in 2001, demonstrated that the peptide helped to lower body weight for four weeks in type 2 diabetes patients who were obese (DiMarchi, Efendic)
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status